531 related articles for article (PubMed ID: 20712869)
1. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety.
Wade AG; Ford I; Crawford G; McConnachie A; Nir T; Laudon M; Zisapel N
BMC Med; 2010 Aug; 8():51. PubMed ID: 20712869
[TBL] [Abstract][Full Text] [Related]
2. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response.
Wade AG; Crawford G; Ford I; McConnachie A; Nir T; Laudon M; Zisapel N
Curr Med Res Opin; 2011 Jan; 27(1):87-98. PubMed ID: 21091391
[TBL] [Abstract][Full Text] [Related]
3. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.
Wade AG; Farmer M; Harari G; Fund N; Laudon M; Nir T; Frydman-Marom A; Zisapel N
Clin Interv Aging; 2014; 9():947-61. PubMed ID: 24971004
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder.
Maras A; Schroder CM; Malow BA; Findling RL; Breddy J; Nir T; Shahmoon S; Zisapel N; Gringras P
J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):699-710. PubMed ID: 30132686
[No Abstract] [Full Text] [Related]
5. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.
Wade AG; Ford I; Crawford G; McMahon AD; Nir T; Laudon M; Zisapel N
Curr Med Res Opin; 2007 Oct; 23(10):2597-605. PubMed ID: 17875243
[TBL] [Abstract][Full Text] [Related]
6. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia.
Luthringer R; Muzet M; Zisapel N; Staner L
Int Clin Psychopharmacol; 2009 Sep; 24(5):239-49. PubMed ID: 19584739
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials.
Lemoine P; Wade AG; Katz A; Nir T; Zisapel N
Integr Blood Press Control; 2012; 5():9-17. PubMed ID: 22346363
[TBL] [Abstract][Full Text] [Related]
8. Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial.
Roth T; Nir T; Zisapel N
Nat Sci Sleep; 2015; 7():13-23. PubMed ID: 25678831
[TBL] [Abstract][Full Text] [Related]
9. Prolonged-release melatonin for insomnia - an open-label long-term study of efficacy, safety, and withdrawal.
Lemoine P; Garfinkel D; Laudon M; Nir T; Zisapel N
Ther Clin Risk Manag; 2011; 7():301-11. PubMed ID: 21845053
[TBL] [Abstract][Full Text] [Related]
10. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects.
Lemoine P; Nir T; Laudon M; Zisapel N
J Sleep Res; 2007 Dec; 16(4):372-80. PubMed ID: 18036082
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic approaches for sleep and rhythms disorders in children with ASD].
Schröder CM; Broquère MA; Claustrat B; Delorme R; Franco P; Lecendreux M; Tordjman S
Encephale; 2022 Jun; 48(3):294-303. PubMed ID: 35120753
[TBL] [Abstract][Full Text] [Related]
12. Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy.
Dolev Z
Arch Womens Ment Health; 2011 Jun; 14(3):269-73. PubMed ID: 21311927
[TBL] [Abstract][Full Text] [Related]
13. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.
Krystal AD; Durrence HH; Scharf M; Jochelson P; Rogowski R; Ludington E; Roth T
Sleep; 2010 Nov; 33(11):1553-61. PubMed ID: 21102997
[TBL] [Abstract][Full Text] [Related]
15. Improvement of sleep quality in elderly people by controlled-release melatonin.
Garfinkel D; Laudon M; Nof D; Zisapel N
Lancet; 1995 Aug; 346(8974):541-4. PubMed ID: 7658780
[TBL] [Abstract][Full Text] [Related]
16. Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin.
Hajak G; Lemme K; Zisapel N
Int Clin Psychopharmacol; 2015 Jan; 30(1):36-42. PubMed ID: 25054634
[TBL] [Abstract][Full Text] [Related]
17. Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial.
Ahn JH; Kim M; Park S; Jang W; Park J; Oh E; Cho JW; Kim JS; Youn J
Parkinsonism Relat Disord; 2020 Jun; 75():50-54. PubMed ID: 32480307
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.
Mayer G; Wang-Weigand S; Roth-Schechter B; Lehmann R; Staner C; Partinen M
Sleep; 2009 Mar; 32(3):351-60. PubMed ID: 19294955
[TBL] [Abstract][Full Text] [Related]
19. Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.
Lyseng-Williamson KA
Drugs Aging; 2012 Nov; 29(11):911-23. PubMed ID: 23044640
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder.
Gringras P; Nir T; Breddy J; Frydman-Marom A; Findling RL
J Am Acad Child Adolesc Psychiatry; 2017 Nov; 56(11):948-957.e4. PubMed ID: 29096777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
